Evotec SE has secured a contract valued at up to $74M from the U.S. Department of Defense to Combat Orthopoxviruses

by GeneOnline
Share To

Evotec SE, a prominent biotechnology company has secured a contract valued at up to $74 million from the U.S. Department of Defense (DOD). The objective of this contract is to accelerate the development of prototypes for monoclonal antibody (mAb) drugs that target orthopoxviruses, a group of viruses including smallpox, monkeypox, cowpox, and vaccinia virus. This collaboration with the DOD marks Evotec’s second project under the Accelerated Antibodies Program.

Related articles: EMA Responds to Monkeypox Public Health Emergency

Evotec Biologics Sets the Pace in Combating Orthopoxviruses

The contract covers the entire drug development process, from discovery to Phase I clinical trials.  With the aid of AI-driven de novo antibody design, Just – Evotec Biologics will evaluate current mAbs and speed up the discovery of new mAbs using its cutting-edge technology platform, J.DESIGN. They will also make use of their skills in intensified continuous manufacturing, cell line and process development, and molecular optimization at the J.POD facility in Redmond, Washington (USA). This all-encompassing strategy ensures that mAb prototypes to combat orthopoxviruses are produced effectively.

The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) of the DOD welcomes the chance to increase collaboration, says Dr. Linda Zuckerman, Executive Vice President Global Head Biotherapeutics at Just – Evotec Biologics. She focuses on the crucial part that biologics development plays in advancing crucial programs for the DOD.

Evotec’s Integrated Solution Earns Praise 

The CEO of Evotec, Dr. Werner Lanthaler, is ecstatic about the expanded collaboration with the DOD. He draws attention to the integrated J.DESIGN platform from Just – Evotec Biologics’ suitability for the quick and affordable development and production of high-quality medical countermeasures. He is happy to offer the DOD an all-encompassing solution that includes research, development, and manufacturing.

Mr. Bruce Goodwin, the Joint Project Lead for CBRND Enabling Biotechnologies, expresses his satisfaction with the collaboration, recognizing the program’s innovation and significance in protecting military personnel.

Orthopoxviruses’ Public Health Impact and the Demand for Effective Antibody Treatments

Orthopoxviruses, including smallpox (variola virus), monkeypox, cowpox, and vaccinia virus, belong to the Poxviridae family. While vaccines exist for some orthopoxviruses like smallpox and cowpox, there are currently no approved antibody treatments for infections caused by these viruses. As a result, orthopoxviruses pose a significant public health concern, emphasizing the urgent need for effective antibody-based treatments.

© All rights reserved. Collaborate with us:
Related Post
Global Expansion between Europe and India of Novel anti-PD-1 mAb Serplulimab
U.S. Government Awards $1.4 Billion to Advance COVID Therapies and Vaccines
Merck Buys Prometheus For $10.8 Billion, Lands Promising Autoimmune Asset
GeneOnline’s Weekly News Highlights: Nov 20-Nov 24
SK Bioscience and Hilleman Laboratories Join Forces for Ebola Vaccine Development
BeiGene to Expand Oncology Pipeline Through ENSEM Therapeutics Partnership
Advancing the Frontiers of Cell and Gene Therapy – An Interview with Dr. Shin Kawamata
Astellas and Pfizer’s Drug Receives FDA Approval as Treatment for High-Risk Prostate Cancer Recurrence
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
Singapore’s NUS Medicine Launches Centre for Sustainable Medicine
2023 Healthcare+ EXPO・Taiwan
Taipei , Taiwan
Scroll to Top